Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 14/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 14/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7104820 | 0.85 | ESR1 (0.58) | ESR1ESR2CA1CA2CA9 | |
| SCHEMBL2368215 | 0.78 | CYP3A4 (0.55) | ESR1ESR2CYP3A4 | |
| SCHEMBL5252597 | 0.77 | ESR1 (0.59) | ESR1ESR2CYP17A1CYP3A4CYP11B1 | |
| SCHEMBL23191190 | 0.75 | CYP3A4 (0.52) | ESR1ESR2CYP3A4 | |
| SCHEMBL4449848 | 0.74 | ESR1 (0.57) | ESR1ESR2CA1CA2CA9 | |
| SCHEMBL3933824 | 0.73 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL28121322 | 0.72 | AHR (0.59) | ESR1ESR2CA1CA2CA9 | |
| SCHEMBL9721304 | 0.71 | ALOX5 (0.48) | ESR1ESR2CA12CA4CA7 | |
| SCHEMBL3925608 | 0.71 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL3924972 | 0.69 | ESR1 (1.00) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225330-A1 | USE OF CERTAIN PHENYL-NAPHTHYL COMPOUNDS THAT DO NOT HAVE SIGNIFICANT AFFINITY TO ER ALPHA OR ER BETA FOR PROTECTION OF NEURONS AND OLIGODENDROCYTES IN THE TREATMENT OF MULTIPLE SCLEROSIS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-09-27 | — | — | US | claimed |
| EP-1835895-A2 | USE OF CERTAIN PHENYL-NAPHTHYL COMPOUNDS THAT DO NOT HAVE SIGNIFICANT AFFINTIY TO ER ALPHA OR BETA FOR PROTECTION OF NEURONS AND OLIGODENDROCYTES IN THE TREATMENT OF MULTIPLE SCLEROSIS | Aventis Pharmaceuticals Inc. (US) | 2007-09-26 | — | — | EP | claimed |
| WO-2006073714-A2 | USE OF CERTAIN PHENYL-NAPHTHYL COMPOUNDS THAT DO NOT HAVE SIGNIFICANT AFFINTIY TO ER ALPHA OR BETA FOR PROTECTION OF NEURONS AND OLIGODENDROCYTES IN THE TREATMENT OF MULTIPLE SCLEROSIS | AVENTIS PHARMACEUTICALS INC. (US) | 2006-07-13 | — | — | WO | claimed |
| US-20020156324-A1 | BIPHENYL COMPOUNDS AND THEIR USE AS OESTROGENIC AGENTS | AVENTIS PHARMA S.A. | 2002-10-24 | — | — | US | claimed |
| US-6448294-B1 | SUCH AS 1,5-DICHORO- OR 5-(4-(2-(DIMETHYLAMINO)ETHOXY)PHENYL) SUBSTITUTED -6-(4-HYDROXYPHENYL)-2-NAPHTHALENOLS; ANTIUTERO-TROPHIC AND REPLACEMENT TREATMENT OF SYMPTOMS LINKED TO MENOPAUSE PARTICULARLY OSTEOPOROSIS | AVENTIS PHARMA S.A. (FR) | 2002-09-10 | — | — | US | claimed |
| EP-0880496-B1 | BIPHENYL COMPOUNDS AND USE THEREOF AS OESTROGENIC AGENTS | AVENTIS PHARMA SA (FR) | 2002-05-29 | — | — | EP | claimed |
| US-6147119-A | TREATING HYPOFOLLICULINIA DISORDERS; ANTICARCINOGENIC, ANTIMETASTASIS AND ANTITUMOR AGENTS; PREMENSTRUAL TENSION, MENOPAUSE, OSTEOPOROSIS | HOECHST MARION ROUSSEL (FR) | 2000-11-14 | — | — | US | claimed |
| EP-0880496-A1 | BIPHENYL COMPOUNDS AND USE THEREOF AS OESTROGENIC AGENTS | HOECHST MARION ROUSSEL (FR) | 1998-12-02 | — | — | EP | claimed |
| WO-1997028116-A1 | BIPHENYL COMPOUNDS AND USE THEREOF AS OESTROGENIC AGENTS | HOECHST MARION ROUSSEL (FR) | 1997-08-07 | — | — | WO | claimed |
| US-20070225330-A1 | USE OF CERTAIN PHENYL-NAPHTHYL COMPOUNDS THAT DO NOT HAVE SIGNIFICANT AFFINITY TO ER ALPHA OR ER BETA FOR PROTECTION OF NEURONS AND OLIGODENDROCYTES IN THE TREATMENT OF MULTIPLE SCLEROSIS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225330-A1 | USE OF CERTAIN PHENYL-NAPHTHYL COMPOUNDS THAT DO NOT HAVE SIGNIFICANT AFFINITY TO ER ALPHA OR ER BETA FOR PROTECTION OF NEURONS AND OLIGODENDROCYTES IN THE TREATMENT OF MULTIPLE SCLEROSIS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225330-A1 | USE OF CERTAIN PHENYL-NAPHTHYL COMPOUNDS THAT DO NOT HAVE SIGNIFICANT AFFINITY TO ER ALPHA OR ER BETA FOR PROTECTION OF NEURONS AND OLIGODENDROCYTES IN THE TREATMENT OF MULTIPLE SCLEROSIS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-7067524-B2 | Substituted phenyl naphthalenes as estrogenic agents | WYETH (US) | 2006-06-27 | — | — | US | disclosed |
| CN-1738788-A | Substituted phenylnaphthalenes as estrogenic agents | WYETH CORP (US) | 2006-02-22 | — | — | CN | disclosed |
| US-6448294-B1 | SUCH AS 1,5-DICHORO- OR 5-(4-(2-(DIMETHYLAMINO)ETHOXY)PHENYL) SUBSTITUTED -6-(4-HYDROXYPHENYL)-2-NAPHTHALENOLS; ANTIUTERO-TROPHIC AND REPLACEMENT TREATMENT OF SYMPTOMS LINKED TO MENOPAUSE PARTICULARLY OSTEOPOROSIS | AVENTIS PHARMA S.A. (FR) | 2002-09-10 | — | — | US | disclosed |
| EP-0880496-B1 | BIPHENYL COMPOUNDS AND USE THEREOF AS OESTROGENIC AGENTS | AVENTIS PHARMA SA (FR) | 2002-05-29 | — | — | EP | disclosed |
| US-6365775-B1 | ANTIUTEROTROPHIC; TREATMENTS OF SYMPTOMS RELATED TO MENOPAUSE AND PREMENSTRAL SYNDRONE | AVENTIS PHARMA S.A. (FR) | 2002-04-02 | — | — | US | disclosed |
| US-6147119-A | TREATING HYPOFOLLICULINIA DISORDERS; ANTICARCINOGENIC, ANTIMETASTASIS AND ANTITUMOR AGENTS; PREMENSTRUAL TENSION, MENOPAUSE, OSTEOPOROSIS | HOECHST MARION ROUSSEL (FR) | 2000-11-14 | — | — | US | disclosed |
| EP-0880496-A1 | BIPHENYL COMPOUNDS AND USE THEREOF AS OESTROGENIC AGENTS | HOECHST MARION ROUSSEL (FR) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997028116-A1 | BIPHENYL COMPOUNDS AND USE THEREOF AS OESTROGENIC AGENTS | HOECHST MARION ROUSSEL (FR) | 1997-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225330-A1 | USE OF CERTAIN PHENYL-NAPHTHYL COMPOUNDS THAT DO NOT HAVE SIGNIFICANT AFFINITY TO ER ALPHA OR ER BETA FOR PROTECTION OF NEURONS AND OLIGODENDROCYTES IN THE TREATMENT OF MULTIPLE SCLEROSIS | ESR2, ESRRG, ESRRB | ESR1 4/4885ESR2 1/4885CA1 2774/4885 |
| US-20020156324-A1 | BIPHENYL COMPOUNDS AND THEIR USE AS OESTROGENIC AGENTS | SHBG, ESR2, CYP19A1 | ESR1 5/4885ESR2 2/4885CA1 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.